Karel Indrák

2.9k total citations
147 papers, 1.6k citations indexed

About

Karel Indrák is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Karel Indrák has authored 147 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Hematology, 68 papers in Genetics and 30 papers in Pathology and Forensic Medicine. Recurrent topics in Karel Indrák's work include Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (30 papers) and Chronic Myeloid Leukemia Treatments (27 papers). Karel Indrák is often cited by papers focused on Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (30 papers) and Chronic Myeloid Leukemia Treatments (27 papers). Karel Indrák collaborates with scholars based in Czechia, United States and Germany. Karel Indrák's co-authors include Edgar Faber, Marie Jarošová, Vladimír Divoký, Josef T. Prchal, Tomáš Papajík, Dagmar Pospı́šilová, Luděk Raida, Vít Procházka, Prem Ponka and Yongli Guan and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Karel Indrák

142 papers receiving 1.6k citations

Peers

Countries citing papers authored by Karel Indrák

Since Specialization

Citations

This map shows the geographic impact of Karel Indrák's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karel Indrák with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karel Indrák more than expected).

Fields of papers citing papers by Karel Indrák

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karel Indrák. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karel Indrák. The network helps show where Karel Indrák may publish in the future.

Co-authorship network of co-authors of Karel Indrák

This figure shows the co-authorship network connecting the top 25 collaborators of Karel Indrák. A scholar is included among the top collaborators of Karel Indrák based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karel Indrák. Karel Indrák is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Increased blood reactive oxygen species and hepcidin in obstructive sleep apnea precludes expected erythrocytosis 2023 ·American Journal of Hematology ·Jihyun Song, Krishna M. Sundar, Monika Horváthová, Radhika Gangaraju, Karel Indrák, Robert D. Christensen, Samuel Genzor, Carsten Lundby, Vladimír Divoký, Tomas Ganz, Josef T. Prchal	7
2	Elevated erythroferrone distinguishes erythrocytosis with inherited defects in oxygen‐sensing pathway from primary familial and congenital polycythaemia 2023 ·British Journal of Haematology ·(unknown), (unknown), Jana Kučerová, Dagmar Pospı́šilová, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Eva Kriegová, Karel Indrák, Edgar Faber, Vladimír Divoký, Monika Horváthová	3
3	Infectious complications of induction treatment for acute myeloid leukaemia using the "7 + 3" protocol without antibiotic prophylaxis - 15 years of experience of one clinical site 2022 ·Biomedical Papers ·Martin Čerňan, Tomáš Szotkowski, (unknown), Milan Kolář, Edgar Faber, Karel Indrák, Tomáš Papajík	1
4	Granulocyte transfusions collected after steroid priming for severe infections during neutropenia: A single center experience 2018 ·Transfusion Clinique et Biologique ·(unknown), (unknown), (unknown), Luděk Raida, Tomáš Szotkowski, (unknown), Peter Rohoň, (unknown), Karel Indrák, Tomáš Papajík, Milan Kolář, Edgar Faber	0
5	A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment 2015 ·Leukemia & lymphoma ·Edgar Faber, (unknown), (unknown), (unknown), (unknown), (unknown), David Friedecký, Tomáš Adam, Marie Jarošová, Karel Indrák	21
6	Genetic Polymorphisms of Platelet Receptors in Patients with Acute Myocardial Infarction and Resistance to Antiplatelet Therapy 2014 ·Genetic Testing and Molecular Biomarkers ·(unknown), Luděk Slavík, Jana Kučerová, (unknown), J. Václavík, Karel Indrák	27
7	Incidence of fecal Enterobacteriaceae producing broad-spectrum beta-lactamases in patients with hematological malignancies 2014 ·Biomedical Papers ·Milan Kolář, (unknown), (unknown), Magdaléna Röderová, (unknown), (unknown), (unknown), Karel Indrák	13
8	High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma 2012 ·Leukemia & lymphoma ·Vít Procházka, Edgar Faber, Luděk Raida, Kateřina Langová, Karel Indrák, Tomáš Papajík	12
9	Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin’s lymphoma using 18F-FDG-PET/CT 2011 ·Neoplasma ·Tomáš Papajík, (unknown), (unknown), А. Малан, (unknown), Vladimír Koza, (unknown), Marek Trněný, (unknown), Zuzana Kubová, Pavel Koranda, (unknown), Jiří Jarkovský, Ladislav Dušek, Karel Indrák	1
10	Synchronous Second Primary Neoplasms Detected by Initial Staging F-18 FDG PET/CT Examination in Patients With Non-Hodgkin Lymphoma 2011 ·Clinical Nuclear Medicine ·Tomáš Papajík, (unknown), (unknown), (unknown), Vít Procházka, Luděk Raida, Zuzana Kubová, Č Neoral, (unknown), (unknown), Bohuslav Melichar, (unknown), M Tichý, Karel Indrák	22
11	Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response 2010 ·International Journal of Hematology ·Edgar Faber, David Friedecký, (unknown), (unknown), (unknown), (unknown), Marie Jarošová, Karel Indrák, Tomáš Adam	10
12	Secondary acute myeloid leukemia – a single center experience 2010 ·Neoplasma ·Tomáš Szotkowski, Peter Rohoň, (unknown), (unknown), (unknown), Karel Indrák	20
13	Precursor T-Lymphoblastic Lymphoma as a Secondary Malignancy in a Young Patient after Successful Treatment of Acute Promyelocytic Leukemia 2009 ·Onkologie ·Tomáš Szotkowski, Marie Jarošová, Edgar Faber, (unknown), (unknown), Tomáš Papajík, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Karel Indrák	4
14	Association of IL6 and CCL2 gene polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation 2009 ·Bone Marrow Transplantation ·(unknown), František Mrázek, Luděk Raida, Peter Jindra, Blanka Vidan‐Jeras, Edgar Faber, Janja Pretnar Oblak, Karel Indrák, Martin Petřek	38
15	PROLONGED SURVIVAL OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA AFTER FIRST-LINE INTENSIVE SEQUENTIAL CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION 2009 ·Biomedical Papers ·Vít Procházka, Edgar Faber, Luděk Raida, (unknown), (unknown), Marie Jarošová, Karel Indrák, Tomáš Papajík	9
16	Gain of chromosome arm 1q in patieznts in relapse and progression of multiple myeloma 2009 ·Cancer Genetics and Cytogenetics ·(unknown), (unknown), Vlastimil Ščudla, (unknown), Jaroslav Bačovský, Karel Indrák, Marie Jarošová	10
17	Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients 2003 ·The Hematology Journal ·(unknown), Jaroslav Bačovský, Karel Indrák, (unknown), (unknown), Edgar Faber, Tomáš Papajík, Zdeněk Adam, Roman Hájek, Pavel Hořák, Arnošt Martínek	1
18	Contribution of Comparative Genomic Hybridization and Fluorescence in situ Hybridization to the Detection of Chromosomal Abnormalities in B-Cell Chronic Lymphocytic Leukemia 2001 ·Oncology Research and Treatment ·Marie Jarošová, Katerina Jedlickova, (unknown), (unknown), Tomáš Papajík, Luděk Raida, (unknown), (unknown), (unknown), (unknown), Karel Indrák	12
19	The T→C mutation at position +96 of the untranslated region 3′ to the terminating codon of the β-globin gene is a rare polymorphism that does not cause a β-thalassemia as previously ascribed 1994 ·Human Genetics ·Vladimír Divoký, E. Baysal, R. Öner, Mehmet Akif Çürük, (unknown), Karel Indrák, Titus H.J. Huisman	7
20	A Czechoslovakian teenager with Hb E-β∘-thalassemia [IVS-I-1 (G → A)] complicated by the presence of an α-globin gene triplication 1991 ·Annals of Hematology ·Karel Indrák, (unknown), (unknown), E. Baysal, V Brabec, (unknown), Jaroslav Čermák, T. H. J. Huisman	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact